It’s a match: use of the radionuclide theranostic pair 133La/225Ac for the radiopharmacological characterization of EGFR-targeted single-domain antibodies
Abstract Background Targeted alpha therapy represents an advanced and rapidly evolving form of precision cancer treatment with increasing importance in recent years. The alpha-emitter 225Ac plays a key role in this clinical development due to its attractive physical and chemical properties. In this...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-06-01
|
| Series: | EJNMMI Radiopharmacy and Chemistry |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s41181-025-00354-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839647958466822144 |
|---|---|
| author | Johanna Trommer Martin Ullrich Falco Reissig Santiago Andres Brühlmann Anne-Kathrin Nitt-Weber Zbynek Novy Katarina Hajduova Daniela Kurfurstova Romana Hendrychova Jan Bouchal Milos Petrik Christin Neuber Wiebke Sihver Sven Stadlbauer Jens Pietzsch Martin Kreller Klaus Kopka Constantin Mamat Kristof Zarschler |
| author_facet | Johanna Trommer Martin Ullrich Falco Reissig Santiago Andres Brühlmann Anne-Kathrin Nitt-Weber Zbynek Novy Katarina Hajduova Daniela Kurfurstova Romana Hendrychova Jan Bouchal Milos Petrik Christin Neuber Wiebke Sihver Sven Stadlbauer Jens Pietzsch Martin Kreller Klaus Kopka Constantin Mamat Kristof Zarschler |
| author_sort | Johanna Trommer |
| collection | DOAJ |
| description | Abstract Background Targeted alpha therapy represents an advanced and rapidly evolving form of precision cancer treatment with increasing importance in recent years. The alpha-emitter 225Ac plays a key role in this clinical development due to its attractive physical and chemical properties. In this context, the macropa chelator has favorable characteristics in terms of labeling conditions and complex stability, making its derivatives exceptionally appealing for 225Ac-labeling of heat-sensitive biomolecules. However, preclinical evaluation of such 225Ac-containing molecules and comprehensive assessment of their pharmacokinetics, dosimetry and radiobiology necessitate a suitable diagnostic counterpart. Due to its attractive radiation properties, 133La represents an adequate positron-emitting radionuclide to form a matched pair with 225Ac for macropa-based radiopharmaceuticals. Herein, we describe the preparation and radiopharmacological characterization of macropa-functionalized, 133La/225Ac-labeled single-domain antibodies (sdAbs) targeting the epidermal growth factor receptor (EGFR) to demonstrate the general suitability of this theranostic pair of radionuclides. Results The synthesis of a clickable, bicyclononyne-modified macropa chelator and its site-specific conjugation to azide-modified, monovalent and biparatopic sdAbs is presented. Subsequent labeling at room temperature (rt) for 15 min resulted in molar activities of 30 MBq/nmol for 133La and 0.5 MBq/nmol for 225Ac, respectively. In vitro studies using the 133La-labeled sdAbs revealed comparable binding characteristics, but an enhanced cellular internalization of the biparatopic variant compared to its monovalent counterparts. This increased uptake consequently resulted in higher cytotoxicity of the 225Ac-labeled biparatopic conjugate. In vivo PET imaging of the 133La-labeled conjugates indicated comparable uptake and retention of the mono- and biparatopic variants in liver and kidneys, with the former showing slightly higher tumor accumulation. Ex vivo biodistribution studies conducted with 225Ac-labeled conjugates largely confirmed the findings obtained by PET imaging, albeit with a marginally higher tumor accumulation of the biparatopic 225Ac-radioimmunoconjugate. Final histological examinations of tumor and kidney tissues showed DNA damage in the renal cortex of the 225Ac-radioimmunoconjugate-treated mice, but no differences in the number of γ-H2AX-positive cells in the corresponding tumor tissues could be detected. Conclusions We present a comprehensive study on the theranostic application of 133La and 225Ac for antibody-based biomolecules and lay the foundation for the future application of this matched pair of radionuclides towards labeling of heat-sensitive, macropa-functionalized radiopharmaceuticals in general. |
| format | Article |
| id | doaj-art-f12ff61d68eb4d5ea5c34b5b9b26640b |
| institution | Matheson Library |
| issn | 2365-421X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | EJNMMI Radiopharmacy and Chemistry |
| spelling | doaj-art-f12ff61d68eb4d5ea5c34b5b9b26640b2025-06-29T11:19:05ZengSpringerOpenEJNMMI Radiopharmacy and Chemistry2365-421X2025-06-0110112710.1186/s41181-025-00354-7It’s a match: use of the radionuclide theranostic pair 133La/225Ac for the radiopharmacological characterization of EGFR-targeted single-domain antibodiesJohanna Trommer0Martin Ullrich1Falco Reissig2Santiago Andres Brühlmann3Anne-Kathrin Nitt-Weber4Zbynek Novy5Katarina Hajduova6Daniela Kurfurstova7Romana Hendrychova8Jan Bouchal9Milos Petrik10Christin Neuber11Wiebke Sihver12Sven Stadlbauer13Jens Pietzsch14Martin Kreller15Klaus Kopka16Constantin Mamat17Kristof Zarschler18Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer ResearchHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer ResearchHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer ResearchHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer ResearchHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer ResearchInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký UniversityInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký UniversityInstitute of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacký University OlomoucInstitute of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacký University OlomoucInstitute of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacký University OlomoucInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký UniversityHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer ResearchHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer ResearchHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer ResearchHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer ResearchHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer ResearchHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer ResearchHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer ResearchHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer ResearchAbstract Background Targeted alpha therapy represents an advanced and rapidly evolving form of precision cancer treatment with increasing importance in recent years. The alpha-emitter 225Ac plays a key role in this clinical development due to its attractive physical and chemical properties. In this context, the macropa chelator has favorable characteristics in terms of labeling conditions and complex stability, making its derivatives exceptionally appealing for 225Ac-labeling of heat-sensitive biomolecules. However, preclinical evaluation of such 225Ac-containing molecules and comprehensive assessment of their pharmacokinetics, dosimetry and radiobiology necessitate a suitable diagnostic counterpart. Due to its attractive radiation properties, 133La represents an adequate positron-emitting radionuclide to form a matched pair with 225Ac for macropa-based radiopharmaceuticals. Herein, we describe the preparation and radiopharmacological characterization of macropa-functionalized, 133La/225Ac-labeled single-domain antibodies (sdAbs) targeting the epidermal growth factor receptor (EGFR) to demonstrate the general suitability of this theranostic pair of radionuclides. Results The synthesis of a clickable, bicyclononyne-modified macropa chelator and its site-specific conjugation to azide-modified, monovalent and biparatopic sdAbs is presented. Subsequent labeling at room temperature (rt) for 15 min resulted in molar activities of 30 MBq/nmol for 133La and 0.5 MBq/nmol for 225Ac, respectively. In vitro studies using the 133La-labeled sdAbs revealed comparable binding characteristics, but an enhanced cellular internalization of the biparatopic variant compared to its monovalent counterparts. This increased uptake consequently resulted in higher cytotoxicity of the 225Ac-labeled biparatopic conjugate. In vivo PET imaging of the 133La-labeled conjugates indicated comparable uptake and retention of the mono- and biparatopic variants in liver and kidneys, with the former showing slightly higher tumor accumulation. Ex vivo biodistribution studies conducted with 225Ac-labeled conjugates largely confirmed the findings obtained by PET imaging, albeit with a marginally higher tumor accumulation of the biparatopic 225Ac-radioimmunoconjugate. Final histological examinations of tumor and kidney tissues showed DNA damage in the renal cortex of the 225Ac-radioimmunoconjugate-treated mice, but no differences in the number of γ-H2AX-positive cells in the corresponding tumor tissues could be detected. Conclusions We present a comprehensive study on the theranostic application of 133La and 225Ac for antibody-based biomolecules and lay the foundation for the future application of this matched pair of radionuclides towards labeling of heat-sensitive, macropa-functionalized radiopharmaceuticals in general.https://doi.org/10.1186/s41181-025-00354-7133La225AcMacropaTargeted alpha therapy TATSingle-domain antibodyTheranostics |
| spellingShingle | Johanna Trommer Martin Ullrich Falco Reissig Santiago Andres Brühlmann Anne-Kathrin Nitt-Weber Zbynek Novy Katarina Hajduova Daniela Kurfurstova Romana Hendrychova Jan Bouchal Milos Petrik Christin Neuber Wiebke Sihver Sven Stadlbauer Jens Pietzsch Martin Kreller Klaus Kopka Constantin Mamat Kristof Zarschler It’s a match: use of the radionuclide theranostic pair 133La/225Ac for the radiopharmacological characterization of EGFR-targeted single-domain antibodies EJNMMI Radiopharmacy and Chemistry 133La 225Ac Macropa Targeted alpha therapy TAT Single-domain antibody Theranostics |
| title | It’s a match: use of the radionuclide theranostic pair 133La/225Ac for the radiopharmacological characterization of EGFR-targeted single-domain antibodies |
| title_full | It’s a match: use of the radionuclide theranostic pair 133La/225Ac for the radiopharmacological characterization of EGFR-targeted single-domain antibodies |
| title_fullStr | It’s a match: use of the radionuclide theranostic pair 133La/225Ac for the radiopharmacological characterization of EGFR-targeted single-domain antibodies |
| title_full_unstemmed | It’s a match: use of the radionuclide theranostic pair 133La/225Ac for the radiopharmacological characterization of EGFR-targeted single-domain antibodies |
| title_short | It’s a match: use of the radionuclide theranostic pair 133La/225Ac for the radiopharmacological characterization of EGFR-targeted single-domain antibodies |
| title_sort | it s a match use of the radionuclide theranostic pair 133la 225ac for the radiopharmacological characterization of egfr targeted single domain antibodies |
| topic | 133La 225Ac Macropa Targeted alpha therapy TAT Single-domain antibody Theranostics |
| url | https://doi.org/10.1186/s41181-025-00354-7 |
| work_keys_str_mv | AT johannatrommer itsamatchuseoftheradionuclidetheranosticpair133la225acfortheradiopharmacologicalcharacterizationofegfrtargetedsingledomainantibodies AT martinullrich itsamatchuseoftheradionuclidetheranosticpair133la225acfortheradiopharmacologicalcharacterizationofegfrtargetedsingledomainantibodies AT falcoreissig itsamatchuseoftheradionuclidetheranosticpair133la225acfortheradiopharmacologicalcharacterizationofegfrtargetedsingledomainantibodies AT santiagoandresbruhlmann itsamatchuseoftheradionuclidetheranosticpair133la225acfortheradiopharmacologicalcharacterizationofegfrtargetedsingledomainantibodies AT annekathrinnittweber itsamatchuseoftheradionuclidetheranosticpair133la225acfortheradiopharmacologicalcharacterizationofegfrtargetedsingledomainantibodies AT zbyneknovy itsamatchuseoftheradionuclidetheranosticpair133la225acfortheradiopharmacologicalcharacterizationofegfrtargetedsingledomainantibodies AT katarinahajduova itsamatchuseoftheradionuclidetheranosticpair133la225acfortheradiopharmacologicalcharacterizationofegfrtargetedsingledomainantibodies AT danielakurfurstova itsamatchuseoftheradionuclidetheranosticpair133la225acfortheradiopharmacologicalcharacterizationofegfrtargetedsingledomainantibodies AT romanahendrychova itsamatchuseoftheradionuclidetheranosticpair133la225acfortheradiopharmacologicalcharacterizationofegfrtargetedsingledomainantibodies AT janbouchal itsamatchuseoftheradionuclidetheranosticpair133la225acfortheradiopharmacologicalcharacterizationofegfrtargetedsingledomainantibodies AT milospetrik itsamatchuseoftheradionuclidetheranosticpair133la225acfortheradiopharmacologicalcharacterizationofegfrtargetedsingledomainantibodies AT christinneuber itsamatchuseoftheradionuclidetheranosticpair133la225acfortheradiopharmacologicalcharacterizationofegfrtargetedsingledomainantibodies AT wiebkesihver itsamatchuseoftheradionuclidetheranosticpair133la225acfortheradiopharmacologicalcharacterizationofegfrtargetedsingledomainantibodies AT svenstadlbauer itsamatchuseoftheradionuclidetheranosticpair133la225acfortheradiopharmacologicalcharacterizationofegfrtargetedsingledomainantibodies AT jenspietzsch itsamatchuseoftheradionuclidetheranosticpair133la225acfortheradiopharmacologicalcharacterizationofegfrtargetedsingledomainantibodies AT martinkreller itsamatchuseoftheradionuclidetheranosticpair133la225acfortheradiopharmacologicalcharacterizationofegfrtargetedsingledomainantibodies AT klauskopka itsamatchuseoftheradionuclidetheranosticpair133la225acfortheradiopharmacologicalcharacterizationofegfrtargetedsingledomainantibodies AT constantinmamat itsamatchuseoftheradionuclidetheranosticpair133la225acfortheradiopharmacologicalcharacterizationofegfrtargetedsingledomainantibodies AT kristofzarschler itsamatchuseoftheradionuclidetheranosticpair133la225acfortheradiopharmacologicalcharacterizationofegfrtargetedsingledomainantibodies |